Evidence map›Paper›PMID 22162556›Full record

ArticleJournal of clinical microbiology2012

Evaluation of any or type-specific persistence of high-risk human papillomavirus for detecting cervical precancer.

Morgan A Marks, Philip E Castle, Mark Schiffman, Patti E Gravitt

Abstract readEvaluation Study
In one paragraph

Article in Journal of clinical microbiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Morgan A MarksDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Philip E Castle
Mark Schiffman
Patti E Gravitt

Funding

INSTITUTIONAL RESEARCH CANCER EPIDEMIOLOGY FELLOWSHIPT32CA009314 · NCI · JOHNS HOPKINS UNIVERSITY · PI Corinne E. Joshu, Meghan Bridgid Moran · 1985 to 2026
$11.2M
RANDOMIZED TRIAL ON THE CLINICAL MANAGEMENT OF ASCUS ANDN01CN055155 · CN · UNIVERSITY OF WASHINGTON · PI KIVIAT, NANCY B. · 1995 to 2000
$559k
CLINICAL MANAGEMENT OF ASCUS/LSIL OF THE UTERINE CERVIXN01CN055153 · CN · WESTAT, INC. · PI ROSENTHAL, JEANNE D · 1995 to 2000
$244k
RANDOMIZED TRIAL ON THE CLINICAL MANAGEMENT OF ASCUSN01CN055157 · CN · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI WALKER, JOAN · 1995 to 1999
–
RANDOMIZED TRIAL ON THE CLINICAL MANAGEMENT OFN01CN055158 · CN · MEDICAL COLLEGE OF GEORGIA (MCG) · PI FERRIS, DARRON D · 1995 to 1999
–
RANDOMIZED TRIAL ON THE CLINICAL MANAGEMENT OF ASCUSN01CN055159 · CN · JOHNS HOPKINS UNIVERSITY · PI KURMAN, ROBERT J. · 1995 to 1999
–
RANDOMIZED TRIAL ON THE CLINICAL MANAGEMENT OF ASCUS ANDN01CN055156 · CN · MAGEE-WOMEN'S HOSPITAL OF UPMC · PI GUIDO, RICHARD S. · 1995 to 2000
–
RANDOMIZED TRIAL ON THE CLINICAL MANAGEMENT OF ASCUS ANDN01CN055154 · CN · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI PARTRIDGE, EDWARD E · 1995 to 2000
–
RANDOMIZED TRIAL ON THE CLINICAL MANAGEMENT OFN01CN055105 · CN · UNIVERSITY OF NEW MEXICO · PI WHEELER, COSETTE M · 1995 to 1999
–
Intramural NIH HHSNCI NIH HHS N01 CN055105NCI NIH HHS N01 CN055153NCI NIH HHS N01 CN055154NCI NIH HHS N01 CN055155NCI NIH HHS N01 CN055156NCI NIH HHS N01 CN055157NCI NIH HHS N01 CN055158NCI NIH HHS N01 CN055159NCI NIH HHS T32 CA0009314NCI NIH HHS T32 CA009314
6 · The paper itself

Abstract

High-risk human papillomavirus (HR-HPV) testing is increasingly important. We therefore examined the impact on accuracy of repeated versus one-time testing, type-specific versus pooled detection, and assay analytic sensitivity. By using a nested case-control design from the ASCUS-LSIL Triage Study, we selected women with incident cervical intraepithelial neoplasia grade 2 or grade 3 (CIN2/3; n = 325) and a random sample of women with <CIN2 as controls (n = 401). HPV DNA status was assessed using hybrid capture 2 (HC2), a pooled test for 13 HR-HPV types, and the linear array (LA) and the line blot assay (LBA), two PCR-based HPV genotyping assays, at enrollment and the 6-month follow-up visit. The relative sensitivity and specificity for different permutations of multiple measurements were compared to a single measurement using marginal regression models. We found that repeat detection of any HR-HPV (by HC2, LA, or LBA) and of type-specific persistence (by LA or LBA) were significantly more specific but less sensitive than use of a single time point measurement of any HR-HPV. Sensitivity decreased and specificity increased further when testing intervals were increased from 12 to 24 months. Including detection of borderline carcinogenic/noncarcinogenic HPV types with HR-HPV types decreased specificity for repeat measures of HPV with no impact on sensitivity. Similar patterns were observed when we used a CIN3 end point. We conclude that assay performance for detecting incident CIN2/3 was affected by which types were included, the analytic sensitivity of the assay, and the testing interval. These trade-offs need to be considered when assessing the potential overall clinical utility of repeated testing for HR-HPV DNA to identify women at risk for CIN2/3.

Indexed as

AdultCase-Control StudiesEarly Detection of CancerFemaleHumansMolecular Diagnostic TechniquesPapillomaviridaePapillomavirus InfectionsRandomized Controlled Trials as TopicSensitivity and SpecificityUterine Cervical Neoplasms

Identifiers

PMID22162556
PMCPMC3264159

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.